GNLX - GENELUX CORPORATION Stock Price, Fair Value and News

$2.30+0.04 (+1.77%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

GNLX RSI Chart

GNLX Valuation

Market Cap

79.4M

Price/Earnings (Trailing)

-2.99

Price/Sales (Trailing)

422.55

Price/Free Cashflow

-3.57

GNLX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

GNLX Fundamentals

GNLX Revenue

Revenue (TTM)

170.0K

Rev. Growth (Yr)

-100%

GNLX Earnings

Earnings (TTM)

-26.5M

Earnings Growth (Yr)

-12.97%

Earnings Growth (Qtr)

16.23%

GNLX Price Action

Last 7 days

16.7%

Last 30 days

6.5%

Last 90 days

20.3%

Trailing 12 Months

-90.9%

GNLX Profitability

Return on Equity

-70.45%

Return on Assets

-58.74%

Free Cashflow Yield

-27.98%

GNLX Financial Health

Current Ratio

6.01

GNLX Investor Care

Shares Dilution (1Y)

31.90%

Diluted EPS (TTM)

-0.93

GNLX Alerts

1 major insider sales recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	8.3M	5.6M	2.9M	170.0K
2022	0	0	0	11.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About GENELUX CORPORATION

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.

CEO	Mr. Thomas Zindrick J.D.
WEBSITE	genelux.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	20

GENELUX CORPORATION Frequently Asked Questions

What is the ticker symbol for GENELUX CORPORATION? What does GNLX stand for in stocks?

GNLX is the stock ticker symbol of GENELUX CORPORATION. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of GENELUX CORPORATION (GNLX)?

As of Wed Oct 02 2024, market cap of GENELUX CORPORATION is 79.78 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GNLX stock?

You can check GNLX's fair value in chart for subscribers.

Is GENELUX CORPORATION a good stock to buy?

The fair value guage provides a quick view whether GNLX is over valued or under valued. Whether GENELUX CORPORATION is cheap or expensive depends on the assumptions which impact GENELUX CORPORATION's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GNLX.

What is GENELUX CORPORATION's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Oct 02 2024, GNLX's PE ratio (Price to Earnings) is -3.01 and Price to Sales (PS) ratio is 422.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GNLX PE ratio will change depending on the future growth rate expectations of investors.